Engineering the Blind: How Physical Pharmacy Solves the Psychedelic Unblinding Crisis

By Sasha Stafford | Principal Scientist & Founder | Prodelic Technologies The greatest bottleneck in the clinical rollout of psychedelic neurotherapeutics isn’t efficacy—it is time. Traditional administration of compounds like psilocybin or LSD relies on simple oral delivery, triggering a rigid pharmacokinetic cascade. The result is often a 6- to 12-hour psychological marathon. This prolonged duration strains clinical infrastructure, requires extensive practitioner oversight,

By Sasha Stafford | Principal Scientist | Prodelic Technologies On September 14, 2026, the U.S. Food and Drug Administration (FDA) hosted a pivotal public hearing titled "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs." With over 1,800 registered attendees and 80 speakers sharing their clinical expertise and lived experiences, the event marked a significant milestone for the psychedelic medicine industry. For those of us at Prodelics, the hearing und

By Sasha Stafford | Principal Scientist & Founder | Prodelic Technologies LLC For decades, the standard in clinical psychedelic research has been relatively uniform: administer a synthetic pill of psilocybin, wait for the patient's liver to metabolize it, and guide them through the resulting hours-long experience. Psilocybin has become the undisputed poster child of the psychedelic renaissance. However, a groundbreaking new study recently published in the Journal of Psychopha

By Sasha Stafford, Principal Scientist and Founder, Prodelic Technologies For the past two decades, modern psychedelic science has operated almost entirely inside the rarefied atmosphere of academic medical centers. Clinical trials conducted at institutions like Johns Hopkins, Imperial College London, and NYU demonstrated remarkable efficacy for treatment-resistant depression, major depressive disorder, and end-of-life anxiety. Yet, these phase 2 and 3 randomized controlled t

Precision Delivery in the Neuroplastogen Era: How the Deliverome Project is Mapping the Future of CNS Therapeutics

One Dose, Lasting Change: Mapping Psilocybin’s Structural Impact on Neural Networks Recent neuroimaging findings published in Nature Communications (Lyons et al., 2026) provide critical empirical evidence for the structural and functional remodeling driven by psilocybin. The study demonstrates that a single high-dose administration initiates both acute functional reorganization and enduring structural neuroplasticity, reinforcing the clinical rationale for episodic, rapid-act

A major paradigm shift in federal drug policy is underway! The executive branch is taking significant steps to accelerate the research and development of psychedelic therapies, with a particular focus on Ibogaine for opioid addiction. This new initiative isn’t just talk; it includes a substantial financial commitment—matching state research investments with $50 million in federal grants (via ARPA-H). A breakdown of the administration’s strategy: 💊 Ibogaine for Opioid Use Dis

Today, Bicycle Day, is celebrated annually on April 19 to commemorate Dr. Albert Hofmann’s intentional discovery of the effects of LSD (lysergic acid diethylamide) in 1943. While Hofmann had synthesized the compound five years earlier at Sandoz Laboratories in Basel, Switzerland, he didn't realize its potency until he accidentally absorbed a small amount through his fingertips on April 16. Three days later, he decided to conduct a self-experiment. The Historic Ride On April 1